Looking to unlock the full potential of your antibody? Whether it’s for your groundbreaking research project or to pave the way for innovative immunotherapies, antibody characterization is key. At ProteoGenix, we redefine the characterization of antibodies, offering an unmatched service that assesses 11 crucial antibody characteristics. We also provide flexible customized antibody characterization solutions for your most challenging projects. With over 3,000 monoclonal antibodies made, 30+ antibodies in clinical and pre-clinical trials, and 3 therapeutic antibodies on the market, we know how to rigorously profile your antibody. The best part? If we find an undesired antibody characteristic, we can fix it. Our one-stop integrated solutions can correct the most challenging antibody features, a service that is unmatched by our competitors. Let’s have a conversation about your antibody characterization needs today!
Antibody Structural Analysis Services
Mass spectroscopy is used to measure antibody molecular weight
Antibody titer is measured using ELISA
SDS-PAGE is used to measure the purity of your antibody
PCR and ELISA are used to identify your antibody’s isotype
De novo MS provides detailed insights into your antibody’s structure
In silico PTM analysis and MS are leveraged to identify antibody PTMs
Antibody Functional Analysis Services
Surface Plasmon Resonance (SPR) is used to identify affinity and affinity towards whole cells (SPRi)
Differential Scanning Fluorimetry (DSF) is used to measure antibody stability
Limulus Amebocytes Lysate assay is used to rigorously measure endotoxin levels
Dynamic light scattering allows us to assess antibody size distribution (aggregation)
Antibody Sequence Analysis Services
Mass spectroscopy is used to identify the amino acid sequence
Receive a sequenced and subcloned antibody DNA sequence
ProteoGenix has over 20 years of expertise with 3 therapeutic antibodies on the market and 30+ in clinical and pre-clinical trials
IP Free Solutions
You always retain the rights to any and all data generated during the antibody characterization process
Our antibody characterization service provides you with the data you will need to obtain regulatory approval for new therapeutics
Cutting Edge Technology
Characterize your antibody with confidence and precision using the latest technological advancements in antibody profiling
Rest assured knowing we use rigorous quality control measures to guarantee the consistency and reliability of your antibody characterization results
Tailor-made approaches to meet your unique antibody characterization needs
Our PhD-level account managers stay in constant communication with you and your team during each step of the project
Investing in antibody characterization is not just a choice; it’s a necessity for progressing your research from the basic science stage to immunotherapy or diagnostic assay. At ProteoGenix, we empower you with the tools and expertise to unlock the full potential of your project.
The process of producing monoclonal antibodies results in a range of antibody modifications that take place at various antibody production stages. This results in a heterogenous monoclonal antibody preparation as the final product. These variations underscore the need for comprehensive characterization of antibodies to ensure the consistent and secure production of therapeutic antibodies.
Whether you’re attempting to engineer an immunotherapeutic or a biomedical research scientist, the success of your project often hinges on the specificity, reliability, and functionality of the antibodies you use. ProteoGenix’s antibody characterization service is important for the following reasons.
Precision in Research:
Optimized Assay Performance:
At ProteoGenix, we employ a comprehensive suite of cutting-edge antibody characterization techniques to ensure the highest quality and reliability of our antibody products. From quantifying antibody titer using ELISA and assessing purity using SDS-PAGE to utilizing advanced techniques like Mass Spectrometry (MS) for in-depth characterization, we leave no stone unturned.
Our dedication to precise and thorough characterization of antibodies sets us apart, ensuring that you receive antibodies that meet the most stringent standards for your research, diagnostics, and therapeutic applications.
Our commitment to excellence also extends to an array of specialized techniques, including surface plasmon resonance (SPR) for precise affinity measurements of immobilized antigens or whole cells (SPRi), de novo Mass Spectrometry for detailed structural insights, and In silico post-translational modification analysis. We also utilize Differential Scanning Fluorimetry (DSF) and Dynamic Light Scattering (DLS) to assess stability and antibody size distribution (antibody aggregates) respectively. We also confirm purity at the molecular level using SEC-HPLC and ensure endotoxin levels are within safe levels using our Limulus Amebocyte Lysate (LAL) protocol.
ProteoGenix is your trusted partner for antibody characterization, providing you with the data and confidence you need for successful antibody development.
Understanding the distinction between antibody concentration and antibody titer is crucial for scientists as it ensures accurate dosing and consistent results in experiments and applications.
Concentration refers to the total antibody content, while titer specifically measures the active, functional antibodies, ensuring proper and effective use in research, diagnostics, or therapeutics.
At ProteoGenix, our commitment to excellence in antibody characterization shines through our cutting-edge methods. We measure antibody concentration using UV spectrophotometry and we measure the amount of functional antibody using ELISA titer assays. These methods provide the sensitivity and reliability needed to accurately identify your antibody’s concentration and titer.
Determining the molecular weight of your custom monoclonal antibody is a pivotal step when developing your antibody for clinical use. It serves as a quality control measure to confirm the antibody’s correct composition and batch-to-batch consistency.
Molecular weight information aids in understanding post-translational modifications, and plays a role in pharmacokinetics, influencing dosing regimens. Regulatory compliance is streamlined with accurate data, while safety concerns are minimized. At ProteoGenix, we rigorously characterize the molecular weight of your antibody using two different approaches.
We begin analyzing the molecular weight of your antibody using SDS-PAGE. This is a robust and widely used method for analyzing antibody molecular weight. This technique allows our antibody experts to determine if your antibody preparations are consistent in size and charge. Next, we couple SDS-PAGE analysis with Mass Spectrometry.
For a deeper and more detailed analysis of antibody molecular weight and antibody heterogeneity, we turn to Mass Spectrometry (MS). MS offers unparalleled accuracy in determining the molecular weight of antibodies. By ionizing and analyzing the mass-to-charge ratio of individual ions, we provide precise measurements, even detecting post-translational modifications and antibody variants. ProteoGenix employs MS to deliver comprehensive insights into your antibody’s molecular weight profile.
Antibody isotyping is the process of identifying the specific class, such as IgG and IgM, and subclasses, such as IgG1, IgG2, IgG3, IgG4, and IgG5. Identifying your antibody class and subclass provides insights into functional properties and predicts performance characteristics in diagnostic and therapeutic applications. This knowledge helps researchers and scientists understand the antibody’s structure and function, and how it might interact with immune cells in vivo. This knowledge is critical when developing antibodies for immunotherapy or diagnostic applications.
At ProteoGenix, we offer comprehensive services that include two established antibody characterization techniques for antibody isotyping, PCR and ELISA.
PCR is a versatile tool in antibody research, allowing us to amplify and identify the unique sequences that define the isotype and subtype of your antibodies. By harnessing the power of PCR, we can confirm the exact genetic makeup of your antibodies, providing you with the confidence that your research or therapeutic development is founded on accurate information. We next confirm the data generated from PCR using ELISA.
ProteoGenix rigorously characterizes the isotype of your monoclonal antibody not only by PCR but also by ELISA to further confirm your antibody’s class and subclass. Together these assays provide reliable antibody isotype determination results.
Utilizing PCR in conjunction with ELISA for isotype identification offers a comprehensive and precise approach, enhancing the accuracy and reliability of your monoclonal antibody characterization.
Antibody Binding Affinity Measurement Services identifies the affinity of your antibody to its target antigen providing an abundance of information about your antibody. This is especially important when considering the development of your antibody for research, diagnostic, and therapeutic purposes. Here’s why it’s crucial:
High-affinity interaction with the target antigen indicates strong and precise binding, which is essential to antibody performance. For instance, a therapeutic antibody with high affinity can selectively and efficiently neutralize or modulate the target, maximizing its therapeutic potential.
Knowing the affinity allows you to optimize the therapeutic dosage. High-affinity antibodies can achieve therapeutic effects at lower concentrations, reducing the required dosage. This not only enhances patient safety but also lowers production costs and minimizes potential side effects associated with high doses.
Affinity influences the duration of the therapeutic effect. High-affinity antibodies tend to have a longer duration of action because they remain bound to the target for extended periods. This prolonged action can be advantageous for chronic conditions, reducing the frequency of administration.
High-affinity antibodies are more likely to bind specifically to the intended target, minimizing the risk of off-target interactions. This specificity is critical for avoiding unintended consequences and side effects in patients.
Affinity is a key factor in determining the selectivity of the therapeutic. A high-affinity antibody is more likely to discriminate between closely related antigens, reducing the risk of cross-reactivity with similar molecules that could compromise safety and efficacy.
Affinity helps define the therapeutic range, which is the concentration range at which the antibody is effective without causing toxicity. Understanding the affinity allows you to establish the appropriate therapeutic range to achieve the desired clinical outcomes.
In a competitive therapeutic landscape, an antibody with superior affinity may outperform others in terms of efficacy, offering a competitive advantage in the market.
Regulatory agencies often require comprehensive characterization of therapeutic antibodies, including affinity determination, as part of the approval process. Demonstrating high affinity and specificity is crucial for obtaining regulatory clearance.
Determining the affinity of your antibody to its target antigen is vital for clinical development. It’s a critical parameter that can make the difference between a successful therapeutic antibody and one that falls short of expectations. Accurate affinity data obtained from thorough characterization is the foundation for successful therapeutic development.
ProteoGenix offers a full suite of antibody services. Therefore, if your antibody’s affinity falls short of expectations ProteoGenix offers affinity maturation services designed to improve your antibody’s affinity to the target antigen.
ProteoGenix employs state-of-the-art Biacore Surface Plasmon Resonance (SPR) technology to precisely and comprehensively assess the affinity of antibodies to their target antigens.
SPR is a cutting-edge, real-time, and label-free technique that allows us to directly measure the binding interactions between antibodies and antigens with exceptional sensitivity and accuracy.
The Biacore SPR technology not only provides quantitative affinity data but also offers insights into:
This information is necessary for understanding how effectively your antibody engages its target, guiding therapeutic development by optimizing dosing regimens.
ProteoGenix also has the ability for high throughput measurement of your antibody’s affinity to samples in suspension such as mammalian cells, bacterial cells, virus-like particles, etc. using our cutting-edge Biacore Surface Plasmon Resonance Imaging (SPRi) technology. Identifying how your monoclonal antibody interacts with target cells is a crucial step in the development of effective immunotherapies such as monoclonal antibodies, bispecific antibodies, and antibody-drug complexes (ADCs). Here’s what SPRi can reveal about your antibody:
ProteoGenix’s use of Biacore SPRi technology to assess antibody interaction with target cells is a powerful and forward-looking approach that provides real-time, physiologically relevant insights into your immunotherapy development.
ProteoGenix can determine your antibody’s amino acid sequence, a crucial step, especially when considering the development of your antibody into a therapeutic. Here’s why it’s vitally important:
Determining the amino acid sequence of your antibody ensures precision, consistency, quality, and regulatory compliance throughout the development process. Accurate sequence data serves as the cornerstone for designing, producing, and optimizing a therapeutic antibody that meets the highest standards of safety and efficacy.
ProteoGenix uses de novo mass spectroscopy to identify the amino acid sequence of each antibody without prior knowledge of the sequence. This method accurately sequences antibodies, ensuring the highest level of precision and reliability in the characterization process. Here’s how it works:
First, the antibody sample is analyzed using mass spectrometry, a technique that measures the mass-to-charge ratio of molecules.
The mass spectrometer generates fragmentation data for the antibody, breaking it into smaller peptide fragments. These fragments are then analyzed to determine their amino acid sequences.
By reconstructing the sequences of individual peptides and aligning them, ProteoGenix can piece together the complete amino acid sequence of the antibody. This approach is particularly valuable when working with antibodies of unknown sequences or when confirming sequences in a non-standard context.
In some cases, the antibody’s amino acid sequence may be known or partially known, especially if it was produced from a hybridoma cell line. ProteoGenix leverages this knowledge by starting the sequencing process with the available information from the hybridoma cell line:
ProteoGenix uses the known or partial sequence from the hybridoma as a starting point. This information serves as a reference to confirm and validate the antibody’s sequence.
Building upon the known segments, ProteoGenix extends the sequencing effort to complete the full amino acid sequence of the antibody. This approach ensures that the antibody’s sequence is fully characterized and accurate.
sequence of the antibody. This approach ensures that the antibody’s sequence is fully characterized and accurate.
By combining these two approaches—de novo mass spectrometry for unbiased sequencing and starting from hybridoma for confirmation—ProteoGenix guarantees a comprehensive and accurate determination of the antibody’s amino acid sequence. This level of precision is essential for the development of high-quality antibodies, whether for research, diagnostics, or therapeutic applications.
Unwanted post-translational modifications (PTMs) in antibodies can significantly impact their stability, efficacy, and safety. These modifications, which may include glycosylation, phosphorylation, or deamidation, can alter the antibody’s structure, charge, or binding affinity, leading to reduced efficacy, increased immunogenicity, and potential adverse reactions in patients. Thorough PTM analysis is crucial to identify and address these modifications, ensuring the development of safe and effective therapeutic antibodies.
Post-translational modification (PTM) mapping of an antibody is indispensable especially when considering the development of your antibody into a therapeutic. Here’s why it’s not just important and why you should consider PTM mapping as a top priority:
PTM mapping is not just important; it’s a fundamental pillar of therapeutic antibody development. It safeguards safety, efficacy, and regulatory compliance, optimizes production, preserves bioactivity, mitigates immunogenicity, enhances stability, and ensures precise dosing.
ProteoGenix employs a comprehensive approach to map an antibody’s PTMs by combining in silico analysis with mass spectrometry. Here’s how this approach works and why it’s highly effective:
1. In Silico Analysis for PTM Site Identification:
In silico analysis refers to computer-based simulations and algorithms used to predict and identify potential PTM sites on antibodies. ProteoGenix leverages the power of computational tools to identify regions where PTMs may occur.
Advanced bioinformatics tools are used to predict PTM sites based on known PTM motifs and structural characteristics. This predictive analysis narrows down the regions of interest, highlighting potential sites for further investigation.
In silico analysis considers a wide range of PTMs, including glycosylation, phosphorylation, acetylation, and more. This diversity ensures that a comprehensive spectrum of modifications is explored.
2. Mass Spectrometry (Mass Spec) Confirmation:
Once potential PTM sites are identified through in silico analysis, ProteoGenix uses mass spectrometry to confirm and precisely characterize the PTMs. Here’s how mass spec contributes to the PTM mapping process:
The antibody sample is subjected to mass spectrometry, a technique that measures the mass-to-charge ratio of molecules in the sample.
TMass spectrometry identifies and quantifies the specific PTMs present on the antibody. It provides detailed information about the type of PTM, the site of modification, and the extent of modification.
Mass spectrometry data is compared with the predictions from in silico analysis. This verification step ensures the accuracy and reliability of the PTM mapping results.
Why This Approach is Effective:
Comprehensive Analysis: Combining in silico analysis with mass spectrometry offers a comprehensive approach to PTM mapping. It maximizes the chances of detecting various PTMs and provides a detailed understanding of their locations.
Efficiency: In silico analysis allows for efficient initial PTM site identification, narrowing down the search space. This efficiency saves time and resources in the subsequent mass spectrometry experiments.
Precision: Mass spectrometry is a high-precision technique that confirms the presence, location, and extent of PTMs. It provides quantitative data, ensuring accurate PTM mapping.
Validation: The synergy between in silico analysis and mass spectrometry allows for rigorous validation of PTM data, enhancing the reliability of the results.
ProteoGenix’s use of this combined approach ensures that PTMs on antibodies are not only identified but also accurately characterized. This is essential for understanding how PTMs impact antibody function, safety, and efficacy, making it a critical step in therapeutic antibody development and characterization.
Ensuring that your antibody remains intact and functional under various conditions is paramount for its efficacy and safety. At ProteoGenix, we understand the significance of stability determination in antibody characterization, and we employ cutting-edge Differential Scanning Fluorimetry (DSF) to achieve this goal.
Why Stability Matters:
Why Choose ProteoGenix’s DSF:
Cutting-Edge Technology: ProteoGenix utilizes state-of-the-art Differential Scanning Fluorimetry (DSF) to assess antibody stability. DSF offers real-time, high-precision thermal stability analysis, allowing us to pinpoint stability issues with precision.
Comprehensive Insights: DSF not only identifies stability problems but also provides insights into the conditions that trigger instability. This information guides formulation strategies and storage recommendations, ensuring your antibody remains robust throughout its lifecycle.
Faster Development: With DSF, we expedite the development process by identifying stability challenges early. This proactive approach minimizes costly setbacks, accelerates development timelines, and markets your therapeutic antibody faster.
Quality Assurance: DSF data is the gold standard for quality assurance. It confirms that each batch of antibodies meets stringent stability criteria, providing batch-to-batch consistency that instills confidence in healthcare providers and patients.
Don’t leave the stability of your therapeutic antibody to chance. Partner with ProteoGenix to harness the power of DSF for robust stability determination.
Whether you’re developing therapeutic antibodies, diagnostic tools, or research reagents, the longevity of your antibodies matters. Understanding their shelf-life stability is pivotal for maintaining their efficacy and reliability over time.
Why Shelf-Life Stability Matters:
When it comes to developing antibodies for therapeutics, diagnostics, or research, colloidal stability is a factor that cannot be overlooked. Understanding and evaluating colloidal stability is key to ensuring that your antibody remains effective and reliable over time. At ProteoGenix, we recognize the pivotal role of colloidal stability assessment in antibody characterization for a multitude of applications.
Why Colloidal Stability Matters:
Don’t leave the stability of your antibodies to chance. Partner with ProteoGenix to assess colloidal stability and ensure that your antibodies remain potent, reliable, and effective in therapeutics, diagnostics, or research. Contact us today to initiate a journey toward robust antibody characterization. Your success begins here.
When crafting antibodies for immunotherapies or diagnostic applications, understanding their propensity to aggregate is paramount. Aggregation can compromise an antibody’s safety, efficacy, and reliability. At ProteoGenix, we emphasize the critical role of aggregate determination in antibody characterization for those in research striving to develop immunotherapies or diagnostic antibodies.
Why Aggregate Determination Matters:
Why Choose ProteoGenix’s SEC-HPLC:
Cutting-Edge Technology: ProteoGenix employs Size-Exclusion Chromatography with High-Performance Liquid Chromatography (SEC-HPLC), a leading technique for aggregate identification. SEC-HPLC separates antibody species by size, allowing for precise analysis of aggregates.
In-Depth Analysis: Our SEC-HPLC techniques not only detect aggregates but also provide insights into their size, composition, and potential causes. This knowledge guides optimization and quality control strategies.
Customized Solutions: We recognize that different applications have unique requirements. Our tailored aggregate determination solutions address your specific needs, whether you’re developing immunotherapies or diagnostic antibodies.
Quality Assurance: With ProteoGenix, you can trust that your antibodies undergo rigorous aggregate evaluation. Our data-driven approach ensures that your products meet the highest quality standards.
Don’t leave the purity of your antibodies to chance. Partner with ProteoGenix to determine their propensity to aggregate and ensure they remain pure, potent, and reliable for your research, immunotherapies, or diagnostics.
When you’re on the path to crafting antibodies for immunotherapies or diagnostics, ensuring their purity is paramount. Measuring endotoxin levels in antibody suspensions is a vital step that cannot be overlooked. At ProteoGenix, we recognize the pivotal role of endotoxin measurement in antibody characterization for individuals in research pursuing immunotherapies or diagnostic antibodies.
Why Endotoxin Measurement Matters:
Why Choose ProteoGenix’s LAL Kit:
Gold-Standard Technology: ProteoGenix utilizes the Limulus Amebocyte Lysate (LAL) kit, the gold standard for endotoxin measurement. LAL is highly sensitive and specific to endotoxins, offering reliable and precise results.
Comprehensive Analysis: Our LAL kit not only detects the presence of endotoxins but also quantifies their levels, allowing for a thorough assessment of endotoxin contamination in your antibody preps.
Customized Solutions: We understand that different applications have unique requirements. Our tailored endotoxin measurement solutions address your specific needs, whether you’re developing immunotherapies or diagnostic antibodies.
Quality Assurance: With ProteoGenix, you can have confidence that your antibodies undergo rigorous endotoxin evaluation. Our data-driven approach ensures that your products meet the highest quality standards.
Don’t compromise on the purity of your antibodies. Partner with ProteoGenix to measure endotoxin levels and ensure that your antibodies remain pure, safe, and reliable for your research, immunotherapies, or diagnostics.
Critical to the development of monoclonal antibodies is the accurate sequencing of antibody DNA. This process is not merely a formality but an essential step that underpins the quality, consistency, and safety of each antibody. Here is why antibody sequencing is important:
It ensures that the antibody’s DNA sequence matches the intended design, preventing potential errors in cloning or synthesis.
It serves as a critical quality control step in antibody production, confirming that the correct genetic material has been used.
DNA sequencing provides a traceable record of the antibody’s genetic information, aiding in batch-to-batch consistency and regulatory compliance. You no longer have to worry about losing your fragile hybridoma cell lines.
Identify any unintended mutations or variations that may affect the antibody’s performance or safety.
DNA sequencing can be crucial for protecting intellectual property rights associated with the antibody’s genetic design.
Here is what you can expect when allowing ProteoGenix to identify the DNA sequence of your antibody.
ProteoGenix’s antibody DNA sequencing service process involves amplifying a DNA copy of the mRNA sequences (cDNA) and inserting it into an expression vector.
Our Antibody Sequencing Process:
1. mRNA extraction
2. Reverse transcription
3. DNA sequencing of at least 5 samples for sequence alignment
4. Sub-cloning into a standard vector
5. PCR amplification
6. Data analysis and detailed report generation
ProteoGenix offers a fully customizable antibody sequencing service with a strong track record of 16 years. Our standardized and exhaustive services ensure optimal performance, including sequencing antibody variable domains (VH, VL) and full-length antibodies (VH, VL, Fc).
Optional services like gene synthesis with codon optimization for specific expression systems (yeast, insect, mammalian) and recombinant antibody production.
Deliverables include a comprehensive report with annotated complementarity determining regions (CDR) sequences, an optional plasmid containing the sequence, and up to 2mg of recombinant antibody upon request
Got a question or need a quote? Message us and we'll get back to you 48 hours or less.
Your cart is currently empty.